Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial
Denise M Ney, Bridget M Stroup, Murray K Clayton, Sangita G Murali, Gregory M Rice, Frances Rohr, Harvey L Levy, Denise M Ney, Bridget M Stroup, Murray K Clayton, Sangita G Murali, Gregory M Rice, Frances Rohr, Harvey L Levy
Abstract
Background: To prevent cognitive impairment, phenylketonuria requires lifelong management of blood phenylalanine (Phe) concentration with a low-Phe diet. The diet restricts intake of Phe from natural proteins in combination with traditional amino acid medical foods (AA-MFs) or glycomacropeptide medical foods (GMP-MFs) that contain primarily intact protein and a small amount of Phe.
Objective: We investigated the efficacy and safety of a low-Phe diet combined with GMP-MFs or AA-MFs providing the same quantity of protein equivalents in free-living subjects with phenylketonuria.
Design: This 2-stage, randomized crossover trial included 30 early-treated phenylketonuria subjects (aged 15-49 y), 20 with classical and 10 with variant phenylketonuria. Subjects consumed, in random order for 3 wk each, their usual low-Phe diet combined with AA-MFs or GMP-MFs. The treatments were separated by a 3-wk washout with AA-MFs. Fasting plasma amino acid profiles, blood Phe concentrations, food records, and neuropsychological tests were obtained.
Results: The frequency of medical food intake was higher with GMP-MFs than with AA-MFs. Subjects rated GMP-MFs as more acceptable than AA-MFs and noted improved gastrointestinal symptoms and less hunger with GMP-MFs. ANCOVA indicated no significant mean ± SE increase in plasma Phe (62 ± 40 μmol/L, P = 0.136), despite a significant increase in Phe intake from GMP-MFs (88 ± 6 mg Phe/d, P = 0.026). AA-MFs decreased plasma Phe (-85 ± 40 μmol/L, P = 0.044) with stable Phe intake. Blood concentrations of Phe across time were not significantly different (AA-MFs = 444 ± 34 μmol/L, GMP-MFs = 497 ± 34 μmol/L), suggesting similar Phe control. Results of the Behavior Rating Inventory of Executive Function were not significantly different.
Conclusions: GMP-MFs provide a safe and acceptable option for the nutritional management of phenylketonuria. The greater acceptability and fewer side effects noted with GMP-MFs than with AA-MFs may enhance dietary adherence for individuals with phenylketonuria. This trial was registered at www.clinicaltrials.gov as NCT01428258.
Keywords: executive function; inborn errors of amino acid metabolism; medical food; phenylalanine; sapropterin dihydrochloride; threonine; tyrosine.
© 2016 American Society for Nutrition.
Figures
References
- Flydal MI, Martinez A. Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 2013;65:341–9.
- Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA, et al. . Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16:188–200.
- Macleod EL, Ney DM. Nutritional management of phenylketonuria. Ann Nestle Eng 2010;68:58–69.
- Singh RH, Rohr F, Frazier D, Cunningham A, Mofidi S, Ogata B, Splett PL, Moseley K, Huntington K, Acosta PB, et al. . Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 2014;16:121–31.
- Walter JH, White FJ. Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 2004;16:41–5.
- Antenor-Dorsey JA, Hershey T, Rutlin J, Shimony JS, McKinstry RC, Grange DK, Christ SE, White DA. White matter integrity and executive abilities in individuals with phenylketonuria. Mol Genet Metab 2013;109:125–31.
- de Groot MJ, Hoeksma M, van Rijn M, Slart RH, van Spronsen FJ. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol Genet Metab 2012;105:566–70.
- Solverson P, Murali SG, Litscher SJ, Blank RD, Ney DM. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet. PLoS One 2012;7:e45165.
- Hansen KE, Ney D. A systematic review of bone mineral density and fractures in phenylketonuria. J Inherit Metab Dis 2014;37:875–80.
- Hennermann JB, Roloff S, Gellermann J, Vollmer I, Windt E, Vetter B, Plockinger U, Monch E, Querfeld U. Chronic kidney disease in adolescent and adult patients with phenylketonuria. J Inherit Metab Dis 2013;36:747–56.
- van Calcar SC, Ney DM. Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino acid-based medical foods for nutrition management of phenylketonuria. J Acad Nutr Diet 2012;112:1201–10.
- Ney DM, Blank RD, Hansen KE. Advances in the nutritional and pharmacological management of phenylketonuria. Curr Opin Clin Nutr Metab Care 2014;17:61–8.
- Etzel MR. Manufacture and use of dairy protein fractions. J Nutr 2004;134:996S–1002S.
- Lim K, van Calcar SC, Nelson KL, Gleason ST, Ney DM. Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU. Mol Genet Metab 2007;92:176–8.
- Sawin EA, De Wolfe TJ, Aktas B, Stroup BM, Murali SG, Steele JL, Ney DM. Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice. Am J Physiol Gastrointest Liver Physiol 2015;309:G590–601.
- Brody EP. Biological activities of bovine glycomacropeptide. Br J Nutr 2000;84(Suppl 1):S39–46.
- Thoma-Worringer C, Sorensen J, Lopez-Findino R. Health effects and technological features of caseinomacropeptide. Int Dairy J 2006;16:1324–33.
- Ney DM, Hull AK, van Calcar SC, Liu X, Etzel MR. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. J Nutr 2008;138:316–22.
- Solverson P, Murali SG, Brinkman AS, Nelson DW, Clayton MK, Yen CL, Ney DM. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab 2012;302:E885–95.
- van Calcar SC, Macleod EL, Gleason ST, Etzel MR, Clayton MK, Wolff JA, Ney DM. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 2009;89:1068–77.
- MacLeod EL, Clayton MK, van Calcar SC, Ney DM. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria. Mol Genet Metab 2010;100:303–8.
- Yi SH, Singh RH. Protein substitute for children and adults with phenylketonuria. Cochrane Database Syst Rev 2015;2:CD004731.
- Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007;92:63–70.
- Guy SC, Isquith, PK, Gioia, GA. Behavior rating inventory of executive function: self-report version. Lutz (FL): Psychological Assessment Resources, Inc; 2004.
- Ney DM, Etzel MR, inventors. Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders. US patent 8,604,168 B2. 2013 Dec 10.
- Schuett V. Low protein food list for PKU. 2nd ed. Seattle (WA): National PKU News; 2002.
- Ney DM, Gleason ST, van Calcar SC, Macleod EL, Nelson KL, Etzel MR, Rice GM, Wolff JA. Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 2009;32:32–9.
- Zhao XH, Wen ZM, Meredith CN, Matthews DE, Bier DM, Young VR. Threonine kinetics at graded threonine intakes in young men. Am J Clin Nutr 1986;43:795–802.
- Darling PB, Grunow J, Rafii M, Brookes S, Ball RO, Pencharz PB. Threonine dehydrogenase is a minor degradative pathway of threonine catabolism in adult humans. Am J Physiol Endocrinol Metab 2000;278:E877–84.
- Stroup BM, Held PK, Williams P, Clayton MK, Murali SG, Rice GM, Ney DM. Clinical relevance of the discrepancy in phenylalanine concentrations analyzed using tandem mass spectrometry compared with ion-exchange chromatography in phenylketonuria. Mol Genet Metab Rep 2016;6:21–6.
- Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797–817.
- Sanjurjo P, Aldamiz L, Georgi G, Jelinek J, Ruiz JI, Boehm G. Dietary threonine reduces plasma phenylalanine levels in patients with hyperphenylalaninemia. J Pediatr Gastroenterol Nutr 2003;36:23–6.
- Lindegren M, Krishnaswami S, Fonnesbeck C, Reimschisel T, Fisher J, Jackson K, Shields T, Sathe N, McPheeters M. Adjuvant treatment for phenylketonuria (PKU). Comparative effectiveness review no.56. AHRQ Publication No 12-EHC035-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2012.
- Mayo Clinic [Internet]. Rochester (MN): Mayo Medical Laboratories; c1995–2016 [cited 2016 Mar 15]. Test ID: AAQP. Available from: .
- Elango R, Chapman K, Rafii M, Ball RO, Pencharz PB. Determination of the tolerable upper intake level of leucine in acute dietary studies in young men. Am J Clin Nutr 2012;96:759–67.
- Manz F, Schmidt H, Scharer K, Bickel H. Acid-base status in dietary treatment of phenylketonuria. Pediatr Res 1977;11:1084–7.
- Smith EA, Macfarlane GT. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol 1996;81:288–302.
- Sawin E, Stroup B, Murali S, Ney D. Metabolomics analysis of phenylketonuria and wild type mice fed casein, amino acid and glycomacropeptide diets. FASEB J 2015;29Suppl 1:745 1. Abstract
- de Oliveira FPMR, Dobbler PT, Mai V, Pylro VS, Waugh SG, Vairo F, Refosco LF, Roesch LFW, Schwartz IVD. Phenylketonuria and gut microbiota: a controlled study based on next generation sequencing. PLoS One 2016 Jun 23; DOI:10.1371/journal.pone.0157513.
- Chiu S, Bergeron N, Williams PT, Bray GA, Sutherland B, Krauss RM. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. Am J Clin Nutr 2016;103:341–7.
- Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43–53.
- Bröer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008;88:249–86.
- Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 2007;91:48–54.
- Hidalgo IJ, Borchardt RT. Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys Acta 1990;1028:25–30.
- MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW. Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis 2003;26:319–26.
- Churchward-Venne TA, Breen L, Di Donato DM, Hector AJ, Mitchell CJ, Moore DR, Stellingwerff T, Breuille D, Offord EA, Baker SK, et al. . Leucine supplementation of a low-protein mixed macronutrient beverage enhances myofibrillar protein synthesis in young men: a double-blind, randomized trial. Am J Clin Nutr 2014;99:276–86.
- Rondanelli M, Klersy C, Terracol G, Talluri J, Maugeri R, Guido D, Faliva MA, Solerte BS, Fioravanti M, Lukaski H, et al. . Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. Am J Clin Nutr 2016;103:830–40.
Source: PubMed